Top CAR-T Cell Therapy Companies in China

Gracell Biotechnologies is focused on developing innovative CAR-T cell therapies, utilizing a next-day manufacturing platform to produce younger and more active T cells, aiming to provide fast and durable responses for cancer and autoimmune disease patients.

CARsgen is a biopharmaceutical company that has developed a promising CAR T-cell therapy, zevorcabtagene autoleucel (zevor-cel or CT053), aimed at treating relapsed/refractory multiple myeloma. With a strong manufacturing presence in both China and the U.S., CARsgen is well-positioned to advance its innovative cell therapies for cancer patients.

Sanyou Biopharmaceuticals Co., Ltd. focuses on developing innovative biological drugs, including CAR-T cell therapy, through its advanced R&D laboratory and leading technology platforms. Their mission is to simplify the R&D process for these therapies, ultimately aiming to enhance the quality of life through innovative treatments.

WuXi AppTec is a global leader in R&D and manufacturing services, specifically supporting the development of cell and gene therapies. They have recently received FDA approval to manufacture Iovance's AMTAGVI™ for advanced melanoma, highlighting their capabilities in advancing innovative treatments.

Cure Genetics is focused on developing innovative CAR-T cell therapies for solid tumors and genetic disorders through its AIMS CAR-NKT platform. With a team experienced in advancing cell therapies from pre-clinical stages to commercial licensure, the company aims to address unmet medical needs and establish itself as a leader in the field.

The company has developed a specialized Jurkart-NFAT-Luc2-CAR19-Cell-Line, which is relevant to CAR-T cell therapy research and development. Their services, including genetically engineered cell lines and advanced gene editing techniques, support in-depth studies of immune system functions and therapeutic advancements.

The company is a clinical-stage biopharmaceutical firm focused on developing innovative small molecule oncology therapies, including precision and immuno-oncology treatments. Their commitment to addressing unmet cancer treatment needs aligns with the evolving landscape of cancer therapies.

Transcenta Holding is a clinical-stage biopharmaceutical company focused on developing therapeutic antibody molecules for oncology, among other indications. Their integrated approach encompasses discovery, research, development, and manufacturing, positioning them as a key player in the biotherapeutics landscape.

InnoCare Pharma Limited is focused on developing innovative therapies for cancer, which may include advanced treatments like CAR-T cell therapy, through its integrated biopharmaceutical platform that enhances R&D and drug development processes. Their commitment to creating first-in-class drugs positions them to potentially contribute to cutting-edge cancer treatment options.

RemeGen is focused on innovative therapies, including its product pipeline with multiple drugs in R&D and commercialization stages. Notably, Telitacicept and Disitamab Vedotin represent significant advancements in targeted therapies.